Zonova develops Z-ROS®, an antimicrobial additive designed to be engineered directly into the polymers of medical devices to create infection-resistant surfaces. The company's licensing model allows global device manufacturers to integrate Z-ROS® into existing product lines without rebuilding supply chains. Early laboratory studies reported by Zonova show greater than 99.99% effectiveness against MRSA and other organisms commonly involved in hospital-acquired infections. Following the recent seed raise, Zonova plans to prioritise integration into vascular access devices, with urology, women's health and orthopaedics planned next. The company has added Dr Pamela Walker Geddes to its board as part of the recent financing. Financially, Zonova has just closed a £2.1m seed round led by THENA Capital with participation from multiple impact and angel investors.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

May 2026